Bavarian Biotech Report 2011/2012 (7MB) - Bio M

SSS International Clinical Research GmbHCROContact:Dr. Michael SigmundLandsberger Str. 23/25D-82110 GermeringPhone: +49 (0) 89 8006500Fax: +49 (0) 89 800650555E-Mail: michael.sigmund@cro-sss.euInternet: www.cro-sss.euKeywords: Clinical Research, Medical Writing, Monitoring, RespiratoryDiseases, Oncology, Cardiovascular Diseases, HematologySSS International Clinical Research provides cost-effective, high quality,comprehensive, and internationally integrated services to develop and commercializethe products of our clients throughout Europe in the pharmaceuticaland biotechnology industries. From experienced project planning andclinical trials management to innovative web-based monitoring tools andexpert consulting, our products and services have been proven for mor thana decade and through many successful projects. From Phase II dose-findingstudies to Phase IV post-marketing studies, and everything in between, weoffer a broad range of therapeutic expertise to meet your clinical trial needs.We have the international experience and local presence to promote yoursuccess.Süd-Chemie AGCHEMICAL INDUSTRY & INDUSTRIAL BIOTECHNOLOGYContact:Dr. Andre KoltermannStaffelseestr. 6D-81477 MünchenPhone: +49 (0) 89 710661-0Fax: +49 (0) 89 710661-122E-Mail: info.crd@sud-chemie.comInternet: www.sud-chemie.comSüd-Chemie, a member of the Clariant Group, Muttenz, Switzerland, is aspecialty chemicals company. The common denominator of all Süd-Chemieproducts and services is the efficient and sparing use of natural resources toenhance the quality of life for humans and the environment. Having itsheadquarters in Munich, it operates on a worldwide scale. The main focus ofSüd-Chemie’s industrial biotechnology activities is on bio-catalysis and biorefining.The company develops energy-efficient processes for themanufacture of biomass-based chemicals and fuels. Süd-Chemie has developeda process which uses enzymatic hydrolysis followed by fermentation toproduce second generation cellulosic bio-ethanol from wheat straw or otheragricultural production residue.Contact:Prof. Dr. Peter BuckelAm Klopferspitz 19D-82152 MartinsriedPhone: +49 (0) 89 30905068-0Fax: +49 (0) 89 30905068-68E-Mail: info@suppremol.comInternet: www.suppremol.comSuppreMol GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Autoimmune Diseases, Rheumatology, Antibody, Drug Development,Peptide/ProteinSuppreMol is a clinical stage biotech company developing first-in-class biopharmaceuticaldrugs based on a new therapeutic principle. Developmentcandidates comprise therapeutic proteins and antibodies with the potentialto cure autoimmune diseases instead of only treating symptoms.SuppreMol is developing its lead product SM101 in proof-of-concept studiesin Primary Immune Thrombocytopenia (ITP), an orphan disease, as wellas Systemic Lupus Erythematosus (SLE). The company is further evaluatingmore common and mainstream diseases such as Rheumatoid Arthritis,Multiple Sclerosis (MS), and Chronic Obstructive Pulmonary Disease (COPD).SuppreMol is a spin-off from the laboratories of the Nobel Laureate Prof.Robert Huber of the Max Planck Institute of Biochemistry in Martinsried,Germany.112